Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Zhou, Xinchun ^a   Mao, Jinghe ^b   Ai, Junmei ^c   Deng, Youping ^d   Roth, Mary R ^e   Pound, Charles ^a   Henegar, Jeffrey ^a   Welti, Ruth ^e   Bigler, Steven A ^f  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b TOUGALOO COLLEGE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e KANSAS STATE UNIVERSITY   (United States)

^f Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROSPHINGOMYELIN; ETHER LINKED PHOSPHATIDYLETHANOLAMINE; LIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PROSTATE SPECIFIC ANTIGEN; SPHINGOMYELIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOINFORMATICS; BLOOD SAMPLING; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPIDOMICS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; PROSTATE CANCER; RANDOM FOREST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ADULT; AGED; COMPUTATIONAL BIOLOGY; HUMANS; LIPIDS; MALE; METABOLOMICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869069944     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048889     Document Type: Article

References (49)

1. Ramírez ML, Nelson EC, Evans CP, (2008) Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis 11 (3): 216-29.
2. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, et al. (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101 (6): 374-83.
3. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, et al. (2002) Over diagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Natl Cancer Inst 94 (13): 981-90.
4. Hamilton RJ, Platz EA, Freedland SJ, (2009) Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker. J Natl Cancer Inst 101 (8): 611-2.
5. Elgamal AA, Holmes EH, Su SL, Tino WT, Simmons SJ, et al. (2000) Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 18 (1): 10-6.
6. Kirby RS, Fitzpatrick JM, Irani J, (2009) Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 103 (4): 441-5.
7. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, et al. (2004) Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 172 (4 Pt 1): 1501-3.
8. Crowe FL, Allen NE, Appleby PN, (2008) Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 88: 1353-63.
9. Freeman VL, Flanigan RC, Meydani M, (2007) Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer. Cancer Causes Control 18 (2): 211-8.
10. Teichert F, Verschoyle RD, Greaves P, Edwards RE, Teahan O, et al. (2008) Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism. Prostate 68 (10): 1035-47.
11. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, et al. (2000) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-245056.
12. Xie Y, Gibbs TC, Mukhin YV, Meier KE, (2002) Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 277 (36): 32516-26.
13. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, et al. (2009) Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia. Prostate 69 (3): 283-92.
14. Kurhanewicz J, Thomas A, Jajodia P, Weiner MW, James TL, et al. (1991) 31P spectroscopy of the human prostate gland in vivo using a transrectal probe. Magn Reson Med 22 (2): 404-13.
15. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, et al. (2008) Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 60 (1): 33-40.
16. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, et al. (2005) Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 65 (24): 11667-75.
17. Gibbs TC, Rubio MV, Zhang Z, Xie Y, Kipp KR, et al. (2009) Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells. Prostate 69 (14): 1493-506.
18. Bravi F, Bosetti C, Scotti L, Talamini R, Montella M, et al. (2007) Food groups and renal cell carcinoma: a case-control study from Italy. Int J Cancer 120 (3): 681-5.
19. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR, (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115 (4): 959-68.
20. Simons K, Ikonen E, (1997) Functional rafts in cell membranes. Nature 387 (6633): 569-72.
21. Pflug BR, Pecher SM, Brink AW, Nelson JB, Foster BA, (2003) Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 57 (3): 245-54.
22. Han X, Gross RW, (2003) Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J Lipid Res 44 (6): 1071-9.
23. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, et al. (2010) Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 51 (11): 3299-305.
24. Kolak M, Westerbacka J, Velagapudi VR, Wågsäter D, Yetukuri L, et al. (2007) Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 56 (8): 1960-8.
25. Pietiläinen KH, Sysi-Aho M, Rissanen A, Seppänen-Laakso T, Yki-Järvinen H, et al. (2007) Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS One 2 (2): e218.
26. Ekroos K, Jänis M, Tarasov K, Hurme R, Laaksonen R, (2010) Lipidomics: A Tool for Studies of Atherosclerosis. Curr Atheroscler Rep 2010 Apr 28.
27. Lankinen M, Schwab U, Erkkilä A, Seppänen-Laakso T, Hannila ML, et al. (2009) Fatty fish intake decreases lipids related to inflammation and insulin signaling-a lipidomics approach. PLoS One 4 (4): e5258.
28. de Mello VD, Lankinen M, Schwab U, Kolehmainen M, Lehto S, et al. (2009) Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52 (12): 2612-5.
29. Graessler J, Schwudke D, Schwarz PE, Herzog R, Shevchenko A, et al. (2009) Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 4 (7): e6261.
30. Han X, Yang J, Yang K, Zhao Z, Abendschein DR, et al. (2007) Alterations in myocardial cardiolipin content and composition occur at the very earliest stages of diabetes: a shotgun lipidomics study. Biochemistry 46 (21): 6417-28.
31. Ollero M, Astarita G, Guerrera IC, Sermet-Gaudelus I, Trudel S, et al. (2011) Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. J Lipid Res 52 (5): 1011-22.
32. Görke R, Meyer-Bäse A, Wagner D, He H, Emmett MR, et al. (2010) Determining and interpreting correlations in lipidomic networks found in glioblastoma cells. BMC Syst Biol 4: 126.
33. He H, Conrad CA, Nilsson CL, Ji Y, Schaub TM, et al. (2007) Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells. Anal Chem 79 (22): 8423-30.
34. Balogh G, Péter M, Liebisch G, Horváth I, Török Z, et al. (2010) Lipidomics reveals membrane lipid remodelling and release of potential lipid mediators during early stress responses in a murine melanoma cell line. Biochim Biophys Acta 1801 (9): 1036-47.
35. Min HK, Lim S, Chung BC, Moon MH, (2011) Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer. Anal Bioanal Chem 399 (2): 823-30.
36. Devaiah S, Roth M, Baughman E, Li M, Tamura P, et al. (2006) Quantitative profiling of polar glycerolipid species from organs of wild-type Arabidopsis and a phospholipase Dal knockout mutant. Phytochemistry 67: 1907-1924.
37. Bartz R, Li WH, Venables B, Zehmer J, Welti R, et al. (2007) Lipidomics reveals adiposomes store ether lipids and mediate phospholipid traffic. J Lipid Res 48: 837-847.
38. Welti R, Li W, Li M, Sang Y, Biesiada H, et al. (2002) Profiling membrane lipids in plant stress responses: Role of phospholipase D{alpha} in freezing-induced lipid changes in Arabidopsis. J. Biol. Chem 277: 31994-32002.
39. Brügger B, Erben G, Sandhoff R, Wieland FT, Lehmann WD, (1997) Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. Proc Natl Acad Sci U S A 94 (6): 2339-44.
40. Liebisch G, Lieser B, Rathenberg J, Drobnik W, Schmitz G, (2004) High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm. Biochim Biophys Acta 1686 (1-2): 108-17.
41. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (1): 66-70 PMID: 15998892.
42. Thompson IM, Ankerst DP, (2007) Prostate-specific antigen in the early detection of prostate cancer. CMAJ 176 (13): 1853-8.
43. Ding J, Sorensen CM, Jaitly N, Jiang H, Orton DJ, et al. (2008) Application of the accurate mass and time tag approach in studies of the human blood lipidome. J Chromatogr B Analyt Technol Biomed Life Sci 871 (2): 243-52.
44. Graessler J, Schwudke D, Schwarz PE, Herzog R, Shevchenko A, et al. (2009) Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 4 (7): e6261.
45. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, et al. (2005) Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 114 (6): 950-6.
46. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (9306): 572-7.
47. Athenstaedt K, Daum G, (1999) Phosphatidic acid, a key intermediate in lipid metabolism. SourceInstitut für Biochemie, Technische Universität, Graz, Austria. Eur J Biochem 266 (1): 1-16.
48. Zhou X, Lawrence TJ, He Z, Pound CR, Mao J, et al. (2011) The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer. Exp Mol Pathol 92 (1): 105-10.
49. Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, et al. (2011) Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage- impact of tissue environment. NMR Biomed 24 (6): 691-9 doi:10.1002/nbm.1738.